• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The role of the sickness funds in the Belgian health care market.

作者信息

Nonneman W, van Doorslaer E

机构信息

Department of Economics, University of Antwerp (UFSIA), The Netherlands.

出版信息

Soc Sci Med. 1994 Nov;39(10):1483-95. doi: 10.1016/0277-9536(94)90242-9.

DOI:10.1016/0277-9536(94)90242-9
PMID:7863360
Abstract

This article reviews some of the salient features of the Belgian health care finance and delivery system. Special attention is paid to the role played by the third-party payers, i.e. the Health Insurance Associations (HIAs) in administering the compulsory national health insurance program. It is shown how, despite extensive government regulation, the markets for GP, specialist and hospital services exhibit fierce competition of the non-price variety. Next, the paper considers the three problems perceived to be the most pressing ones at present: (i) the problem of raising sufficient revenues to cover the public share of health expenditures; (ii) the (related) cost containment problem; and (iii) the problem of ensuring efficiency through appropriate incentive mechanisms. Finally, two recently proposed options for reform are discussed and complemented with a third proposal based on the ideas of regulated competition. It is concluded that strengthening the role of the third-party payers remains crucial in any attempt to reshape the system to make it efficient and affordable while keeping it equitable.

摘要

相似文献

1
The role of the sickness funds in the Belgian health care market.
Soc Sci Med. 1994 Nov;39(10):1483-95. doi: 10.1016/0277-9536(94)90242-9.
2
Forming and reforming the market for third-party purchasing of health care: a German perspective.构建和重塑医疗保健第三方购买市场:德国视角
Soc Sci Med. 1994 Nov;39(10):1473-81. doi: 10.1016/0277-9536(94)90241-0.
3
Managed competition in The Netherlands: lessons from five years of health care reform.荷兰的管理式竞争:五年医疗改革的经验教训
Aust Health Rev. 1995;18(1):9-27.
4
Price elasticities in the German Statutory Health Insurance market before and after the health care reform of 2009.2009年医疗改革前后德国法定医疗保险市场的价格弹性
Health Policy. 2015 May;119(5):654-63. doi: 10.1016/j.healthpol.2015.01.014. Epub 2015 Jan 30.
5
Supervision in social health insurance: a four country study.社会医疗保险中的监管:一项四国研究。
Health Policy. 2005 Mar;71(3):333-46. doi: 10.1016/j.healthpol.2003.12.017.
6
Risk adjustment in Switzerland.瑞士的风险调整。
Health Policy. 2003 Jul;65(1):63-74. doi: 10.1016/s0168-8510(02)00117-3.
7
Reforming the Israeli health care market.
Soc Sci Med. 1994 Nov;39(10):1447-57. doi: 10.1016/0277-9536(94)90239-9.
8
The Clinton health care reform proposal: efficiency, fairness, and the role of government.克林顿医疗保健改革提案:效率、公平与政府的作用。
Health Care Manag. 1994 Aug;1(1):1-22.
9
Managing the health care market in developing countries: prospects and problems.发展中国家医疗保健市场的管理:前景与问题
Health Policy Plan. 1994 Sep;9(3):237-51. doi: 10.1093/heapol/9.3.237.
10
Has solidarity survived? A comparative analysis of the effect of social health insurance reform in four European countries.团结精神尚存吗?四个欧洲国家社会医疗保险改革效果的比较分析。
J Health Polit Policy Law. 2003 Aug;28(4):585-614. doi: 10.1215/03616878-28-4-585.

引用本文的文献

1
Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
Pharmacoeconomics. 2002;20(7):485-97. doi: 10.2165/00019053-200220070-00006.
2
Risk adjustment and the fear of markets: the case of Belgium.风险调整与对市场的担忧:比利时的案例
Health Care Manag Sci. 2000 Feb;3(2):121-30. doi: 10.1023/a:1019089223462.
3
Drug use in relation to clinical activities as an instrument for prospective drug budgeting. The Belgian experience.
Pharmacoeconomics. 1996 Mar;9(3):246-63. doi: 10.2165/00019053-199609030-00006.